Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy

Allan W Taylor, Barudi Mosimaneotsile, Unami Mathebula, Anikie Mathoma, Ritah Moathlodi, Irene Theebetsile, Taraz Samandari, Allan W Taylor, Barudi Mosimaneotsile, Unami Mathebula, Anikie Mathoma, Ritah Moathlodi, Irene Theebetsile, Taraz Samandari

Abstract

Objective: While 6- to 12-month courses of isoniazid for tuberculosis prevention are considered safe in pregnant women, the effects of longer-term isoniazid prophylaxis or isoniazid in combination with antiretroviral therapy (ART) are not established in human-immunodeficiency-virus-(HIV-) infected women who experience pregnancy during the course of therapy.

Design: Nested study of pregnancy outcomes among HIV-infected women participating in a placebo-controlled, TB-prevention trial using 36 months daily isoniazid. Pregnancy outcomes were collected by interview and record review.

Results: Among 196 pregnant women, 103 (52.6%) were exposed to isoniazid during pregnancy; all were exposed to antiretroviral drugs. Prior to pregnancy they had received a median of 341 days (range 1-1095) of isoniazid. We observed no isoniazid-associated hepatitis or other severe isoniazid-associated adverse events in the 103 women. Pregnancy outcomes were 132 term live births, 42 premature births, 11 stillbirths, 8 low birth weight, 6 spontaneous abortions, 4 neonatal deaths, and 1 congenital abnormality. In a multivariable model, neither isoniazid nor ART exposure during pregnancy was significantly associated with adverse pregnancy outcome (adjusted odds ratios 0.6, 95% CI: 0.3-1.1 and 1.8, 95% CI 0.9-3.6, resp.).

Conclusions: Long-term isoniazid prophylaxis was not associated with adverse pregnancy outcomes, such as preterm delivery, even in the context of ART exposure.

References

    1. Reid A, Scano F, Getahun H, et al. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. The Lancet Infectious Diseases. 2006;6(8):483–495.
    1. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. The Lancet. 2011;377(9777):1588–1598.
    1. Martinson N, Barnes G, Msandiwa R, Moulton L, Gray G, McIntyre J, et al. Novel regimens for treating latent TB in HIV-infected adults in South Africa: a randomized clinical trial. Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada.
    1. World Health Organization. Guidelines for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource Constrained Settings. Geneva, Switzerland: World Health Organization; 2011.
    1. UNAIDS. AIDS epidemic update, November 2009.
    1. Ojikutu B, Makadzange AT, Gaolathe T. Scaling up ART treatment capacity: lessons learned from South Africa, Zimbabwe, and Botswana. Current HIV/AIDS Reports. 2008;5(2):94–98.
    1. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recommendations and Reports. 2000;49(RR06):1–54.
    1. Mosimaneotsile B, Mathoma A, Chengeta B, et al. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a botswana experience, 2004–2006. Journal of Acquired Immune Deficiency Syndromes. 2010;54(1):71–77.
    1. Snider DE, Jr., Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. The American Review of Respiratory Disease. 1992;145(2):494–497.
    1. Franks AL, Binkin NJ, Snider DE, Jr., Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Reports. 1989;104(2):151–155.
    1. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection—United States, 2004–2008. Morbidity and Mortality Weekly Report. 59(8):224–229.
    1. Wilson EA, Thelin TJ, Dilts PV., Jr. Tuberculosis complicated by pregnancy. The American Journal of Obstetrics and Gynecology. 1973;115(4):526–529.
    1. Scheinhorn DJ, Angelillo VA. Antituberculous therapy in pregnancy. Risks to the fetus. Western Journal of Medicine. 1977;127(3):195–198.
    1. Kancherla V, Romitti PA, Caspers KM, Puzhankara S, Morcuende JA. Epidemiology of congenital idiopathic talipes equinovarus in Iowa, 1997–2005. The American Journal of Medical Genetics A. 2010;152(7):1695–1700.
    1. Moorthi RN, Hashmi SS, Langois P, Canfield M, Waller DK, Hecht JT. Idiopathic talipes equinovarus (ITEV) (Clubfeet) in Texas. The American Journal of Medical Genetics. 2005;132(4):376–380.
    1. Chung CS, Nemechek RW, Larsen IJ, Ching GH. Genetic and epidemiological studies of clubfoot in Hawaii. General and medical considerations. Human Heredity. 1969;19(4):321–342.
    1. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 Through 31 July 2009. Wilmington, NC, USA: Registry Coordinating Center; 2009.
    1. European Collaborative Study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14(18):2913–2920.
    1. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18(17):2337–2339.
    1. Parekh N, Ribaudo H, Souda S, et al. Risk factors for very preterm delivery and delivery of very-small-for-gestational-age infants among HIV-exposed and HIV-unexposed infants in Botswana. International Journal of Gynecology and Obstetrics. 2011;115(1):20–25.
    1. Bussmann H, Wester CW, Wester CN, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. Journal of Acquired Immune Deficiency Syndromes. 2007;45(3):269–273.
    1. Tuomala RE, Watts H, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. Journal of Acquired Immune Deficiency Syndromes. 2005;38(4):449–473.
    1. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. The New England Journal of Medicine. 2002;346(24):1863–1870.
    1. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007;21(5):607–615.
    1. Stratton P, Tuomala RE, Abboud R, et al. Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1999;20(2):179–186.
    1. Newell ML, Dunn DT, Peckham CS, Semprini AE, Pardi G. Vertical transmission of HIV-1: maternal immune status and obstetric factors. The European collaborative study. AIDS. 1996;10(14):1675–1681.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa